• Corpus ID: 8136355

Vitaxin applied molecular evolution.

@article{Mikecz2000VitaxinAM,
  title={Vitaxin applied molecular evolution.},
  author={Katalin Mikecz},
  journal={Current opinion in investigational drugs},
  year={2000},
  volume={1 2},
  pages={
          199-203
        }
}
  • K. Mikecz
  • Published 1 October 2000
  • Medicine
  • Current opinion in investigational drugs
Vitaxin is a humanized version of LM-609 (an mAb licensed from the Scripps Research Institute and Dr David Cheresh in May 1994, which blocks the integrin receptor, alpha v beta 3) [172038]. It is in phase II trials for the potential treatment of leiomyosarcoma [316471] and is also being studied in phase I trials as an anti-inflammatory and potential rheumatoid arthritis therapy [364031,313665]. Vitaxin and non-peptides are under evaluation for use in the treatment of other diseases in which… 
View on PubMed
28 Citations
Highly Influential Citations
1
Background Citations
14
Methods Citations
1

28 Citations

Effects of Vitaxin®, a novel therapeutic in trial for metastatic bone tumors, on osteoclast functions in vitro

It is shown that Vitaxin's inhibitory effects on osteoclasts can be modulated by factors known to alter the conformation of αvβ3, and that this effect was enhanced in cells pretreated with M‐CSF.

Ligands to the integrin receptor αvβ3

A number of patents and patent applications have recently appeared describing peptidic and non-peptidic αvβ3 antagonists as potential therapeutic agents for the treatment of osteoporosis, cancer, diabetic retinopathy and rheumatoid arthritis.

Phase I Evaluation of a Fully Human Anti–αv Integrin Monoclonal Antibody (CNTO 95) in Patients with Advanced Solid Tumors

CNTO 95 was generally well tolerated and associated with one episode of grade III and four episodes of grade II infusion-related fever, and six patients received extended therapy, including one patient with a prolonged response.

Integrins: Molecular targets in cancer therapy

The parallel development of integrin antagonists as imaging tools for patient selection may accelerate the discovery of new avenues for their use.

Ligand-mimetic anti-aIIbβ3 antibody PAC-1 inhibits tyrosine signaling, proliferation and lung colonization of melanoma cells

Preclinical data suggest that the ectopic expression of αIIbβ3 in melanoma cells can be exploited as a novel target of antibody therapy of melanoma.

Multiple FAS1 domains and the RGD motif of TGFBI act cooperatively to bind αvβ3 integrin, leading to anti-angiogenic and anti-tumor effects.

AlphaV Beta 3 Integrin : A Novel Therapeutic Target In Rheumatoid Arthritis

Integrin alpha V beta 3 (vitronectin receptor) has been the focus of intensive research because of its major role in several distinct processes, particularly osteoclast mediated bone resorption, angiogenesis (pathological neovascularisation) and macrophage dependant inflammation in rheumatoid arthritis.

Engineered cystine knot peptides that bind αvβ3, αvβ5, and α5β1 integrins with low‐nanomolar affinity

There is a critical need for compounds that target cell surface integrin receptors for applications in cancer therapy and diagnosis. We used directed evolution to engineer the Ecballium elaterium…

Anti‐angiogenic drugs: from bench to clinical trials

The current approaches for the discovery of new compounds that inhibit angiogenesis are discussed, with emphasis on the clinical developmental status of anti‐angiogenic drugs.

Engineered cystine-knot peptides that bind alpha(v)beta(3) integrin with antibody-like affinities.